International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 8, Issue 3 (May-June 2026) Submit your research before last 3 days of June to publish your research paper in the issue of May-June.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 8 Issue 3
May-June 2026

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Comparative Efficacy and Safety of Finerenone versus Spironolactone in the Management of Diabetic Kidney Disease with Proteinuria

Author(s) Dr. Subhadip Ganguly, Dr. Harsh Bansal, Dr. Santhosh Reddy Gade
Country India
Abstract Background:
Diabetic kidney disease (DKD) with persistent proteinuria remains a leading cause of end-stage renal disease (ESRD) and cardiovascular mortality worldwide, despite optimal use of renin–angiotensin system (RAS) inhibitors and sodium–glucose cotransporter-2 (SGLT2) inhibitors. Mineralocorticoid receptor antagonists (MRAs) provide additional renoprotective effects by reducing inflammation and fibrosis. Spironolactone, a first-generation steroidal MRA, has demonstrated reductions in albuminuria but is often limited by adverse events such as hyperkalemia and gynecomastia. Finerenone, a novel non-steroidal MRA with higher receptor selectivity and lower lipophilicity, has shown significant renal and cardiovascular benefits with a reduced risk of hyperkalemia in large phase III trials. However, a direct comparative evaluation of these agents in DKD with proteinuria is lacking.
Objective:
To systematically compare the efficacy and safety of finerenone versus spironolactone in the management of DKD with proteinuria, highlighting their impact on renal outcomes, cardiovascular endpoints, and adverse event profiles.
Methods:
A comprehensive literature search of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov was conducted through September 2025. Randomized controlled trials (RCTs), observational studies, and meta-analyses evaluating finerenone or spironolactone in adults with DKD and proteinuria were included. Primary efficacy outcomes were reduction in urinary albumin-to-creatinine ratio (UACR) and preservation of estimated glomerular filtration rate (eGFR). Secondary outcomes included composite kidney failure endpoints and major adverse cardiovascular events (MACE). Safety outcomes assessed were hyperkalemia incidence, endocrine-related adverse effects, and treatment discontinuation rates.
Results:
Evidence from the FIDELIO-DKD (n=5,734) and FIGARO-DKD (n=7,437) trials demonstrated that finerenone significantly reduced progression to kidney failure (hazard ratio [HR]: 0.82) and lowered risk of cardiovascular events (HR: 0.87) compared to placebo, with a moderate increase in hyperkalemia (18% vs 9% in placebo) but low discontinuation rates (~2%). Spironolactone trials in DKD populations reported reductions in proteinuria ranging from 30–40%, often comparable or slightly greater than finerenone; however, rates of hyperkalemia were substantially higher (up to 20–25%), with 8–10% of patients requiring discontinuation. Additionally, spironolactone was associated with gynecomastia and menstrual irregularities due to its non-selective steroidal activity, adverse effects not observed with finerenone. Indirect comparisons suggest that finerenone provides more durable renal and cardiovascular benefits while maintaining a superior safety and tolerability profile.
Conclusion:
Both spironolactone and finerenone effectively reduce proteinuria in DKD, yet finerenone offers a more favorable balance of efficacy and safety. Spironolactone remains effective in lowering albuminuria but carries a higher risk of hyperkalemia and endocrine-related adverse effects, limiting its long-term use. Finerenone, supported by robust large-scale RCTs, emerges as the preferred therapeutic option for DKD with proteinuria, particularly in patients at high risk of adverse events. Nevertheless, the absence of direct head-to-head trials underscores the need for future comparative studies to refine individualized treatment strategies.
Keywords Finerenone, Spironolactone, Diabetic Kidney Disease, Proteinuria, Mineralocorticoid Receptor Antagonist, Hyperkalemia, Cardiorenal Outcomes, Safety
Field Biology
Published In Volume 7, Issue 5, September-October 2025
Published On 2025-09-16
DOI https://doi.org/10.36948/ijfmr.2025.v07i05.55882
View / Download PDF File

Share this



E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 8 Isu 2Cover Page Vol 8 Isu 1Cover Page Vol 7 Isu 6

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9687-828-838 editor@ijfmr.com
Powered by Sky Research Publication and Journals